ReviewChinese clinical oncology2015
New approaches in primary central nervous system lymphoma.
Review in Chinese clinical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Novel Therapies in Primary Central Nervous System Lymphoma.Clinical pharmacology : advances and applications · 2025Review
- Primary Central Nervous System Lymphoma Presenting as a Solitary Fourth Ventricular Mass: A Case Report.Cureus · 2024Article
- Absence of enhancement in a lesion does not preclude primary central nervous system T-cell lymphoma: A case report.World journal of clinical cases · 2024Article
- Efficacy of endoscopic management of primary central nervous system lymphoma: a multicentric study and literature review.Journal of neuro-oncology · 2022Review
- The PI3K/AKT/mTOR signaling pathway is aberrantly activated in primary central nervous system lymphoma and correlated with a poor prognosis.BMC cancer · 2022Article
- Epstein-Barr Virus and Neurological Diseases.Frontiers in molecular biosciences · 2021Review
- Primary Central Nervous System Involvement in Peripheral T-Cell Lymphoma: A Case Report.Taehan Yongsang Uihakhoe chi · 2021Article
- Overcoming the Blood-Brain Barrier: Functionalised Chitosan Nanocarriers.Pharmaceutics · 2020Review
- Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen.Clinical lymphoma, myeloma & leukemia · 2020Article
- Curative effect of methotrexate combined with teniposide in the treatment of primary central nervous system lymphoma.Oncology letters · 2020Article
- A new prognostic score for disease progression and mortality in patients with newly diagnosed primary CNS lymphoma.Cancer medicine · 2020Observational
- Epstein-Barr Virus Infection in the Development of Neurological Disorders.Drug discovery today. Disease models · 2020Article
- Clinical value of magnetic resonance imaging in identifying multiple cerebral gliomas from primary central nervous system lymphoma.Oncology letters · 2019Article
- High-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China.Cancer medicine · 2019Article
- Hematopoietic stem cell transplantation in primary central nervous system lymphoma: a review of the literature.International journal of hematology · 2019Review
- Imaging features (CT, MRI, MRS, and PET/CT) of primary central nervous system lymphoma in immunocompetent patients.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2019Article
- Recurrent Epstein-Barr Virus-positive (EBV+) Primary Central Nervous System Lymphoma (PCNSL) in a Patient with Clinical Features of Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids (CLIPPERS).Internal medicine (Tokyo, Japan) · 2019Article
- The diagnostic role and dynamic changes in cerebrospinal fluid neopterin during treatment of patients with primary central nervous system lymphoma.Cancer medicine · 2018Article
- Is deep brain involvement in intracranial primary central nervous system lymphoma of importance for penetration of chemotherapeutic agents?Neuroradiology · 2018Article
- Evaluation of Memorial Sloan-Kettering Cancer Center and International Extranodal Lymphoma Study Group prognostic scoring systems to predict Overall Survival in intracranial Primary CNS lymphoma.Brain and behavior · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Primary central nervous system lymphoma (PCNSL) has long been associated with an inferior prognosis compared to other aggressive non-Hodgkin's lymphomas (NHLs). However, during the past 10 years an accumulation of clinical experience has demonstrated that long-term progression-free survival (PFS) can be attained in a major proportion of PCNSL patients who receive dose-intensive consolidation chemotherapy and avoid whole brain radiotherapy. One recent approach that has reproducibly demonstrated efficacy for newly diagnosed PCNSL patients is an immunochemotherapy combination regimen used during induction that consists of methotrexate, temozolomide, and rituximab followed by consolidative infusional etoposide plus high-dose cytarabine (EA), administered in first complete remission (CR). Other high-dose chemotherapy-based consolidative regimens have shown efficacy as well. Our goal in this review is to update principles of diagnosis and management as well as data regarding the molecular pathogenesis of PCNSL, information that may constitute a basis for development of more effective therapies required to make additional advances in this phenotype of aggressive NHL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.